摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-(hydroxymethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one | 253687-16-0

中文名称
——
中文别名
——
英文名称
7-(hydroxymethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one
英文别名
7-(hydroxymethyl)-4H-1,4-benzoxazin-3-one
7-(hydroxymethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one化学式
CAS
253687-16-0
化学式
C9H9NO3
mdl
——
分子量
179.175
InChiKey
GWVPOHCHOSLYSA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    206-208 °C
  • 沸点:
    431.8±45.0 °C(Predicted)
  • 密度:
    1.340±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    58.6
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933599090

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Design, Synthesis and Antitumor Assessment of Phenylureas Bearing 5-Fluoroindolin-2-one Moiety
    作者:Yunrui Cai、Tong Chen、Huajian Zhu、Hongbin Zou
    DOI:10.2174/1573406416666200206123319
    日期:2020.11.6
    Objective: This study focuses on the design, synthesis, and antitumor evaluation of phenyl ureas bearing 5-fluoroindolin-2-one moiety. Methods: Three sets of phenylureas were designed and synthesized and their antiproliferative ability was measured against four human carcinoma cell lines (Hela, Eca-109, A549, and MCF-7) via MTT assay. In vivo anticancer activity was further evaluated in xenograft models
    背景:新型抗肿瘤药的开发仍然非常需要。 目的:本研究的重点是带有5-氟吲哚-2-酮部分的苯基脲的设计,合成和抗肿瘤评估。 方法:设计并合成了三套苯基脲,并通过MTT法测定了它们对四种人类癌细胞系(Hela,Eca-109,A549和MCF-7)的抗增殖能力。在人乳腺癌的异种移植模型(MCF-7)中进一步评估了体内抗癌活性。 结果:总共合成了二十一种新化合物,并通过1H和13C NMR以及HR-MS进行了表征。最初构建了三组化合物(1a‒1c,2a‒2c和3a‒3c),并评估了这些分子对Hela,Eca-109,A549和MCF-7的初步抗增殖活性,突出了间位取代的苯基脲(1a‒1c)是最具细胞毒性的药物。然后设计并合成了一系列间位取代的苯基脲衍生物(1d‒1o)用于结构-活性关系研究。大多数新化合物显示出理想的细胞毒性,其中化合物1g对测试的人类癌细胞表现出最显着的细胞毒性作用,IC50值为1
  • 5-Quinoline derivatives having an anti-bacterial activity
    申请人:Dale Glenn
    公开号:US20100324030A1
    公开(公告)日:2010-12-23
    The present invention describes novel anti-bacterial compounds of the formula (I). These compounds are, amongst others, of interest as inhibitors of DNA gyrase and topoisomerases, for example of topoisomerase II and IV.
    本发明描述了通式(I)的新型抗菌化合物。这些化合物,除其他外,作为DNA促旋酶和拓扑异构酶的抑制剂,例如拓扑异构酶II和IV,具有研究价值。
  • SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES
    申请人:Masarykova univerzita
    公开号:EP3556755A1
    公开(公告)日:2019-10-23
    The invention provides compounds represented by the structural formula (1): wherein R1, R2, R3, R4, R5, R6 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.
    本发明提供了结构式(1)所代表的化合物: 其中 R1、R2、R3、R4、R5、R6 如权利要求中定义。这些化合物是核酸酶的抑制剂,特别适用于增殖性疾病、神经退行性疾病和其他基因组不稳定性相关疾病的治疗和/或预防方法。
  • A Series of 6- and 7-Piperazinyl- and -Piperidinylmethylbenzoxazinones with Dopamine D4 Antagonist Activity:  Discovery of a Potential Atypical Antipsychotic Agent
    作者:Thomas R. Belliotti、David J. Wustrow、Wouter A. Brink、Kim T. Zoski、Yu-Hsin Shih、Steven Z. Whetzel、Lynn M. Georgic、Ann E. Corbin、Hyacinth C. Akunne、Thomas G. Heffner、Thomas A. Pugsley、Lawrence D. Wise
    DOI:10.1021/jm990277d
    日期:1999.12.1
    As part of a program to develop dopamine D4 antagonists for the treatment of schizophrenia, we discovered a series of 6- and 7-(phenylpiperazinyl)- and -(phenylpiperidinyl)methylbenzoxazinones through mass screening of our compound library. A structure-activity relationship SAR study was carried out involving substituents on the phenyl ring, and several selective D4 antagonists were identified. The 7-substituted benzoxazinones showed more activity in neurochemical and behavioral tests than the 6-substituted series. One of the most potent and selective compounds (26) was found to have potent activity in animal tests predictive of antipsychotic activity in humans after oral administration. This paper describes the SAR of the benzoxazinone series and the preclinical characterization of 26.
  • US7476675B2
    申请人:——
    公开号:US7476675B2
    公开(公告)日:2009-01-13
查看更多